AANS Online Scientific Sessions: Tumor-Longitudinal Analysis of Serum-derived Extracellular RNA for Monitoring of Treatment Response to Dacomitinib in Adult Patients with EGFR Amplified Recurrent Glioblastoma

Longitudinal Analysis of Serum-derived Extracellular RNA for Monitoring of Treatment Response to Dacomitinib in Adult Patients with EGFR Amplified Recurrent Glioblastoma

Video Transcription

Video Summary

In this video, Anudeep Ekula, a postdoctoral fellow in Dr. Carter's lab, presents on an RNA sequencing-based liquid biopsy strategy for monitoring response to targeted therapy in patients with recurrent glioblastoma. Liquid biopsy refers to the analysis of biofluids such as blood, CSF, urine, and saliva to diagnose and monitor diseases. The focus of their group is the extracellular vesicle (EV) fraction, which contains genetic and proteomic cargo from parent cells. They conducted a clinical trial evaluating the efficacy of the drug docomitinib in patients with recurrent EGFR-amplified glioblastoma. By analyzing EV RNA profiles, they were able to identify potential biomarkers for tumor presence, patient stratification, and response to therapy. The study highlights the potential of EV RNA profiling in guiding treatment strategies. The presenter acknowledges the organizers of AANS for the opportunity and the support from NIH and NCI's liquid biopsy consortium.

Asset Subtitle

Anudeep Yekula, MD

Keywords

RNA sequencing

liquid biopsy

targeted therapy

recurrent glioblastoma

extracellular vesicles